258 related articles for article (PubMed ID: 18079360)
1. Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study.
Heimberger AB; Sun W; Hussain SF; Dey M; Crutcher L; Aldape K; Gilbert M; Hassenbusch SJ; Sawaya R; Schmittling B; Archer GE; Mitchell DA; Bigner DD; Sampson JH
Neuro Oncol; 2008 Feb; 10(1):98-103. PubMed ID: 18079360
[TBL] [Abstract][Full Text] [Related]
2. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.
Sampson JH; Aldape KD; Archer GE; Coan A; Desjardins A; Friedman AH; Friedman HS; Gilbert MR; Herndon JE; McLendon RE; Mitchell DA; Reardon DA; Sawaya R; Schmittling R; Shi W; Vredenburgh JJ; Bigner DD; Heimberger AB
Neuro Oncol; 2011 Mar; 13(3):324-33. PubMed ID: 21149254
[TBL] [Abstract][Full Text] [Related]
3. The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients.
Paff M; Alexandru-Abrams D; Hsu FP; Bota DA
Hum Vaccin Immunother; 2014; 10(11):3322-31. PubMed ID: 25625931
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.
Mitchell DA; Cui X; Schmittling RJ; Sanchez-Perez L; Snyder DJ; Congdon KL; Archer GE; Desjardins A; Friedman AH; Friedman HS; Herndon JE; McLendon RE; Reardon DA; Vredenburgh JJ; Bigner DD; Sampson JH
Blood; 2011 Sep; 118(11):3003-12. PubMed ID: 21768296
[TBL] [Abstract][Full Text] [Related]
5. Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice.
Sanchez-Perez LA; Choi BD; Archer GE; Cui X; Flores C; Johnson LA; Schmittling RJ; Snyder D; Herndon JE; Bigner DD; Mitchell DA; Sampson JH
PLoS One; 2013; 8(3):e59082. PubMed ID: 23527092
[TBL] [Abstract][Full Text] [Related]
6. Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy.
Saraswathula A; Reap EA; Choi BD; Schmittling RJ; Norberg PK; Sayour EJ; Herndon JE; Healy P; Congdon KL; Archer GE; Sanchez-Perez L; Sampson JH
Cancer Immunol Immunother; 2016 Feb; 65(2):205-11. PubMed ID: 26759007
[TBL] [Abstract][Full Text] [Related]
7. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
[TBL] [Abstract][Full Text] [Related]
8. Cellular-based immunotherapies for patients with glioblastoma multiforme.
Xu X; Stockhammer F; Schmitt M
Clin Dev Immunol; 2012; 2012():764213. PubMed ID: 22474481
[TBL] [Abstract][Full Text] [Related]
9. Pathological changes after autologous formalin-fixed tumor vaccine therapy combined with temozolomide for glioblastoma - three case reports - .
Sakamoto N; Ishikawa E; Yamamoto T; Satomi K; Nakai K; Sato M; Enomoto T; Morishita Y; Takano S; Ohno T; Tsuboi K; Matsumura A
Neurol Med Chir (Tokyo); 2011; 51(4):319-25. PubMed ID: 21515959
[TBL] [Abstract][Full Text] [Related]
10. Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy.
Fadul CE; Fisher JL; Hampton TH; Lallana EC; Li Z; Gui J; Szczepiorkowski ZM; Tosteson TD; Rhodes CH; Wishart HA; Lewis LD; Ernstoff MS
J Immunother; 2011 May; 34(4):382-9. PubMed ID: 21499132
[TBL] [Abstract][Full Text] [Related]
11. Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme.
Fadul CE; Fisher JL; Gui J; Hampton TH; Côté AL; Ernstoff MS
Neuro Oncol; 2011 Apr; 13(4):393-400. PubMed ID: 21339188
[TBL] [Abstract][Full Text] [Related]
12. Effects of concomitant temozolomide and radiation therapies on WT1-specific T-cells in malignant glioma.
Chiba Y; Hashimoto N; Tsuboi A; Oka Y; Murao A; Kinoshita M; Kagawa N; Oji Y; Hosen N; Nishida S; Sugiyama H; Yoshimine T
Jpn J Clin Oncol; 2010 May; 40(5):395-403. PubMed ID: 20364021
[TBL] [Abstract][Full Text] [Related]
13. Advances in Immunotherapy for Glioblastoma Multiforme.
Huang B; Zhang H; Gu L; Ye B; Jian Z; Stary C; Xiong X
J Immunol Res; 2017; 2017():3597613. PubMed ID: 28299344
[TBL] [Abstract][Full Text] [Related]
14. Immune modulation associated with vascular endothelial growth factor (VEGF) blockade in patients with glioblastoma.
Thomas AA; Fisher JL; Hampton TH; Christensen BC; Tsongalis GJ; Rahme GJ; Whipple CA; Steel SE; Davis MC; Gaur AB; Lewis LD; Ernstoff MS; Fadul CE
Cancer Immunol Immunother; 2017 Mar; 66(3):379-389. PubMed ID: 27942839
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme.
Hunn MK; Bauer E; Wood CE; Gasser O; Dzhelali M; Ancelet LR; Mester B; Sharples KJ; Findlay MP; Hamilton DA; Hermans IF
J Neurooncol; 2015 Jan; 121(2):319-29. PubMed ID: 25366363
[TBL] [Abstract][Full Text] [Related]
16. Human umbilical vein endothelial cell vaccine therapy in patients with recurrent glioblastoma.
Tanaka M; Tsuno NH; Fujii T; Todo T; Saito N; Takahashi K
Cancer Sci; 2013 Feb; 104(2):200-5. PubMed ID: 23106822
[TBL] [Abstract][Full Text] [Related]
17. Concomitant chemoradiotherapy followed by adjuvant temozolomide improves survival in glioblastoma multiforme.
Abrey LE
Curr Neurol Neurosci Rep; 2005 May; 5(3):167-8. PubMed ID: 15865881
[No Abstract] [Full Text] [Related]
18. Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme.
Baumann F; Bjeljac M; Kollias SS; Baumert BG; Brandner S; Rousson V; Yonekawa Y; Bernays RL
J Neurooncol; 2004; 67(1-2):191-200. PubMed ID: 15072467
[TBL] [Abstract][Full Text] [Related]
19. Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination.
Batich KA; Reap EA; Archer GE; Sanchez-Perez L; Nair SK; Schmittling RJ; Norberg P; Xie W; Herndon JE; Healy P; McLendon RE; Friedman AH; Friedman HS; Bigner D; Vlahovic G; Mitchell DA; Sampson JH
Clin Cancer Res; 2017 Apr; 23(8):1898-1909. PubMed ID: 28411277
[No Abstract] [Full Text] [Related]
20. Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response.
Hashimoto N; Tsuboi A; Kagawa N; Chiba Y; Izumoto S; Kinoshita M; Kijima N; Oka Y; Morimoto S; Nakajima H; Morita S; Sakamoto J; Nishida S; Hosen N; Oji Y; Arita N; Yoshimine T; Sugiyama H
Cancer Immunol Immunother; 2015 Jun; 64(6):707-16. PubMed ID: 25772149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
